Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAUNA trial
2022-502703-30-00Phase 4Authorised
- Sponsor
- Antwerp University Hospital
- Start
- Jun 2023
- Modality
- Peptides, Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of octreotide, lanreotide, lutetium Lu 177 dotatate, sunitinib and everolimus in Gastroenteropancreatic Carcinoid Tumor (4 arms), sponsored by Antwerp University Hospital. Primary endpoints: Progression-free survival in PRRT substudy, Progression-free survival in targeted therapy substudy and 2 more. Planned start Jun 2023; status: authorised.
02
Drugs
octreotidelanreotidelutetium Lu 177 dotatatesunitinibeverolimus
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on 2022-502703-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502703-30-00.